Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
system characterized by inflammatory demyelination and axonal/neuronal damage. The …
Clinical outcome measures in multiple sclerosis: a review
H Inojosa, D Schriefer, T Ziemssen - Autoimmunity reviews, 2020 - Elsevier
A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …
detect MS progression. It provides important data for physicians on their daily practice as …
A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis
Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical
relapses, no magnetic resonance imaging (MRI) disease activity and no disability …
relapses, no magnetic resonance imaging (MRI) disease activity and no disability …
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition
H Inojosa, U Proschmann, K Akgün, T Ziemssen - Journal of neurology, 2021 - Springer
Secondary progressive multiple sclerosis (SPMS) is the second most common form of
multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will …
multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will …
Pregnancy management in multiple sclerosis and other demyelinating diseases
RM Bove, MK Houtchens - CONTINUUM: Lifelong Learning in …, 2022 - journals.lww.com
PURPOSE OF REVIEW Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders
(NMOSDs) are chronic autoimmune demyelinating conditions of the central nervous system …
(NMOSDs) are chronic autoimmune demyelinating conditions of the central nervous system …
Antibody-mediated cell depletion therapies in multiple sclerosis
A Mariottini, PA Muraro, JD Lünemann - Frontiers in Immunology, 2022 - frontiersin.org
Development of disease-modifying therapies including monoclonal antibody (mAb)-based
therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over …
therapeutics for the treatment of multiple sclerosis (MS) has been extremely successful over …
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
PA Calabresi, DL Arnold… - Multiple Sclerosis …, 2021 - journals.sagepub.com
Objective: To understand how longitudinal serum neurofilament light chain (sNfL) patterns
can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether …
can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether …
Visualizing the central nervous system: imaging tools for multiple sclerosis and neuromyelitis optica spectrum disorders
J Kuchling, F Paul - Frontiers in Neurology, 2020 - frontiersin.org
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are
autoimmune central nervous system conditions with increasing incidence and prevalence …
autoimmune central nervous system conditions with increasing incidence and prevalence …
Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?
Background: Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more
robustly with clinical disability than traditional, lesion-based metrics. We compare Structural …
robustly with clinical disability than traditional, lesion-based metrics. We compare Structural …
Thalamic atrophy without whole brain atrophy is associated with absence of 2-year NEDA in multiple sclerosis
K Hänninen, M Viitala, T Paavilainen, JO Karhu… - Frontiers in …, 2019 - frontiersin.org
Purpose: To study which brain volume measures best differentiate early relapsing MS (RMS)
and secondary progressive MS (SPMS) patients and correlate with disability and cognition …
and secondary progressive MS (SPMS) patients and correlate with disability and cognition …